

Patient Name: EXAMPLE, PATIENT

Med. Rec. #:

DOB:

Gender:

Physician(s): UNIDENTIFIED PHYSICIAN

Client:

Location:

Billing #:

Copy To:

Accession #:

Taken:

Received:

Reported:

Specimen(s) Received

A: Thin prep slides, urine

Clinical History

Microscopic hematuria


Cytogenetic Analysis

Interpretation

Positive: FISH scanning revealed greater than or equal to 4 cells with gains of two or more chromosomes 3 (D3Z1), 7 (D7Z1) or 17 (D17Z1).

Comment: Total 85 cells were examined for this specimen, and six of those cells showed gains of chromosomes 3, 7, and 17 (trisomies 3, 7, and 17) and two copies of chromosome 9.

Reference: Riesz et al., Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathology Oncology Research, Vol 13, No 3, 2007.



ABNORMAL FISH UROVYSION

Result

nuc ish(D3Z1x3,D7Z1x3,CDKN4Ax2,D17Z1x3)[6/85]

Molecular Cytogenetic Analysis:

FISH

No. of Cells Analyzed: 85

No. of Cells Imaged: 2

Method: UroVysion™ (Abbott Molecular Inc., Des Plaines, IL 60018) bladder cancer kit is an FDA approved test designed to detect aneuploidy of chromosome 3, 7, 17 and loss of chromosome 9p21 locus via Fluorescence in situ hybridization (FISH) in urine specimens from patients with hematuria suspected of having bladder cancer. The test uses centromere probes for chromosome 3 (D3Z1), 7 (D7Z1), 17 (D17Z1) and a locus specific probe for 9p21.

DNA Probe	*Patient Cells	
	Total # Cells Studied	Abnormal #

CEP3/CEP7/CDKN4A(9p21)/CEP17	85	gains of chromosomes 3, 7, and 176	6
------------------------------	----	---------------------------------------	---

*Concurrent controls are run.

Laboratory test results should always be considered in the context of clinical observations. This FISH test is performed using a Vysis FDA modified UroVysion Kit.

Technical and Professional services performed at: med fusion, 2501 South State Hwy 121, Suite 1100, Lewisville, TX 75067

Electronically Signed Out Zhenjun Lou, Ph.D., DABMG